Zealand Pharma submits New Drug Application for glepaglutide in short bowel syndrome

  Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS) dependent on parenteral support.

https://www.biospace.com/article/releases/zealand-pharma-submits-new-drug-application-to-the-us-fda-for-glepaglutide-in-short-bowel-syndrome/